Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.

  • Heme · MyelomaRecruitingPhase 3NCT07222761

    A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Regeneron Pharmaceuticals · 60 locations · Updated 2026-11-18

  • Heme · MyelomaRecruitingPhase 3NCT07555938

    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

    Hoffmann-La Roche · 105 locations · Updated 2026-11-18

  • Heme · MyelomaRecruitingPhase 3NCT07649525

    Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

    University of Leeds · 5 locations · Updated 2026-11-16

  • Heme · MyelomaNot yet recruitingPhase 3NCT07903506

    To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

    Kite, A Gilead Company · Locations not reported · Updated 2026-11-16

  • Heme · MyelomaRecruitingPhase 3NCT07285239

    Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

    PrECOG, LLC. · 3 locations · Updated 2026-11-12

  • Heme · MyelomaNot yet recruitingPhase 3NCT07903272

    A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

    Janssen Research & Development, LLC · Locations not reported · Updated 2026-11-04

  • Heme · MyelomaRecruitingPhase 3NCT07665450

    A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

    Janssen Research & Development, LLC · 103 locations · Updated 2026-11-03

  • Heme · MyelomaRecruitingPhase 3NCT05552222

    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

    Janssen Research & Development, LLC · 270 locations · Updated 2026-11-03

  • Heme · MyelomaNot yet recruitingPhase 3NCT07910903

    Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma

    Keymed Biosciences Co.Ltd · 1 locations · Updated 2026-11-02

  • Heme · MyelomaRecruitingPhase 3NCT06615479

    A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 141 locations · Updated 2026-10-29

  • Heme · MyelomaRecruitingPhase 3NCT05623020

    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

    Pfizer · 180 locations · Updated 2026-10-27

  • Heme · MyelomaNot yet recruitingPhase 2 / Phase 3NCT07887984

    Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma

    Alliance for Clinical Trials in Oncology · Locations not reported · Updated 2026-10-22

  • Heme · MyelomaRecruitingPhase 3NCT07735637

    A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

    AstraZeneca · 114 locations · Updated 2026-10-21

  • Heme · MyelomaNot yet recruitingPhase 3NCT07887672

    A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma

    Kite, A Gilead Company · Locations not reported · Updated 2026-10-21

  • Heme · MyelomaRecruitingPhase 2 / Phase 3NCT07095452

    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    AbbVie · 49 locations · Updated 2026-10-19

  • Heme · MyelomaRecruitingPhase 3NCT07624513

    D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

    Dana-Farber Cancer Institute · 3 locations · Updated 2026-10-09

  • Heme · MyelomaRecruitingPhase 3NCT06918002

    Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

    Intergroupe Francophone du Myelome · 69 locations · Updated 2026-09-30

  • Heme · MyelomaRecruitingPhase 3NCT07391657

    A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

    AstraZeneca · 143 locations · Updated 2026-09-29

  • Heme · MyelomaRecruitingPhase 3NCT07764978

    Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

    AstraZeneca · 124 locations · Updated 2026-08-14

  • Heme · MyelomaRecruitingPhase 3NCT07742215

    A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)

    Biocad · 16 locations · Updated 2026-08-03

  • Heme · MyelomaNot yet recruitingPhase 3NCT07740486

    A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

    Polish Myeloma Consortium · Locations not reported · Updated 2026-07-31

  • Heme · MyelomaNot yet recruitingPhase 3NCT07671287

    GMMG-HD11/DSMM XXI/64007957MMY3010

    University of Heidelberg Medical Center · Locations not reported · Updated 2026-06-26

  • Heme · MyelomaRecruitingPhase 3NCT05558319

    NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

    PETHEMA Foundation · 68 locations · Updated 2026-06-25

  • Heme · MyelomaRecruitingPhase 3NCT06679101

    A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

    GlaxoSmithKline · 181 locations · Updated 2026-04-22

  • Heme · MyelomaRecruitingPhase 3NCT06932562

    A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

    European Myeloma Network B.V. · 59 locations · Updated 2026-03-25

  • Heme · MyelomaRecruitingPhase 3NCT07297329

    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Sinocelltech Ltd. · 1 locations · Updated 2026-01-29

  • Heme · MyelomaRecruitingPhase 2 / Phase 3NCT04513639

    The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

    Oslo University Hospital · 13 locations · Updated 2025-03-20

  • Heme · MyelomaRecruitingPhase 2 / Phase 3NCT06879379

    KPD Consolidation After ASCT in NDMM Patients

    Peking University People's Hospital · 3 locations · Updated 2025-03-17

  • Heme · MyelomaRecruitingPhase 2 / Phase 3NCT05665140

    Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

    University Hopsital Schleswig Holstein Campus Lübeck · 6 locations · Updated 2024-12-11

  • Heme · Myeloma, AMLRecruitingPhase 2NCT07437950

    Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 69 locations · Updated 2026-11-18

  • Heme · Myeloma, AMLRecruitingPhase 2NCT06672146

    Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 138 locations · Updated 2026-11-16

  • Heme · Myeloma, AMLRecruitingPhase 2NCT06317649

    Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 229 locations · Updated 2026-11-12

  • Heme · Myeloma, AMLRecruitingPhase 2NCT05554406

    Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 227 locations · Updated 2026-11-09

  • Heme · MyelomaRecruitingPhase 2NCT06993675

    Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

    Noffar Bar · 3 locations · Updated 2026-11-06

  • Heme · MyelomaRecruitingPhase 2NCT05979363

    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-11-04

  • Heme · Myeloma, AMLRecruitingPhase 2NCT06917911

    Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

    National Cancer Institute (NCI) · 81 locations · Updated 2026-11-04

  • Heme · MyelomaRecruitingPhase 2NCT06948084

    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

    National Cancer Institute (NCI) · 32 locations · Updated 2026-11-04

  • Heme · MyelomaRecruitingPhase 2NCT07149857

    A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

    Janssen Research & Development, LLC · 20 locations · Updated 2026-11-03

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT07099391

    A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

    Memorial Sloan Kettering Cancer Center · 7 locations · Updated 2026-11-02

  • Heme · MyelomaRecruitingPhase 2NCT05091372

    Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-11-02

Showing 1–40 of 120. Older studies

More hematologic trials (152) that list MRD only as a secondary endpoint
  • Heme · MyelomaRecruitingPhase 3NCT07728188

    A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

    AbbVie · 7 locations · Updated 2026-11-17

  • Heme · MyelomaNot yet recruitingPhase 3NCT07933432

    A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131

    Qilu Pharmaceutical Co., Ltd. · Locations not reported · Updated 2026-11-12

  • Heme · MyelomaRecruitingPhase 3NCT06152575

    MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    Pfizer · 268 locations · Updated 2026-11-12

  • Heme · MyelomaRecruitingPhase 3NCT05730036

    A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

    Regeneron Pharmaceuticals · 159 locations · Updated 2026-11-06

  • Heme · MyelomaRecruitingPhase 3NCT07393282

    A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

    Regeneron Pharmaceuticals · 33 locations · Updated 2026-11-04

  • Heme · MyelomaRecruitingPhase 3NCT07258511

    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

    Janssen Research & Development, LLC · 157 locations · Updated 2026-11-03

  • Heme · MyelomaRecruitingPhase 3NCT05519085

    A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Celgene · 266 locations · Updated 2026-10-30

  • Heme · MyelomaRecruitingPhase 3NCT07518186

    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    Janssen Research & Development, LLC · 173 locations · Updated 2026-09-25

  • Heme · MyelomaRecruitingPhase 3NCT07623798

    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

    Innovent Biologics (Suzhou) Co. Ltd. · 1 locations · Updated 2026-09-17

  • Heme · MyelomaRecruitingPhase 3NCT05020236

    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

    Pfizer · 237 locations · Updated 2026-08-24

  • Heme · MyelomaRecruitingPhase 3NCT07772024

    Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

    CellCentric Ltd. · 1 locations · Updated 2026-08-19

  • Heme · MyelomaRecruitingPhase 3NCT06508983

    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

    Hangzhou Sumgen Biotech Co., Ltd. · 12 locations · Updated 2026-07-10

  • Heme · MyelomaRecruitingPhase 3NCT05561387

    Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    SWOG Cancer Research Network · 397 locations · Updated 2026-06-10

  • Heme · MyelomaRecruitingPhase 3NCT07138209

    A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

    Qilu Pharmaceutical Co., Ltd. · 1 locations · Updated 2026-05-22

  • Heme · MyelomaNot yet recruitingPhase 3NCT07569757

    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 49 locations · Updated 2026-05-08

  • Heme · MyelomaRecruitingPhase 3NCT07452198

    A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

    Genrix (Shanghai) Biopharmaceutical Co., Ltd. · 1 locations · Updated 2026-03-25

  • Heme · MyelomaNot yet recruitingPhase 3NCT06895512

    A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

    Shanghai Henlius Biotech · 1 locations · Updated 2025-03-26

  • Heme · MyelomaRecruitingPhase 3NCT03562169

    The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

    University of Leeds · 91 locations · Updated 2018-06-19

  • Heme · MyelomaRecruitingPhase 2NCT06577441

    Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 152 locations · Updated 2026-11-18

  • Heme · MyelomaRecruitingPhase 2NCT06103838

    18F-Fluciclovine PET/CT in Multiple Myeloma

    National Cancer Institute (NCI) · 1 locations · Updated 2026-11-12

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06049290

    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

    Nanjing Leads Biolabs Co.,Ltd · 21 locations · Updated 2026-11-12

  • Heme · MyelomaRecruitingPhase 2NCT07931391

    SKCD in Early Relapsed/Refractory Multiple Myeloma

    Beijing Chao Yang Hospital · 1 locations · Updated 2026-11-12

  • Heme · MyelomaNot yet recruitingPhase 2NCT07695740

    Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

    Excyte Biopharma Ltd · 1 locations · Updated 2026-11-06

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT05583617

    A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

    Hoffmann-La Roche · 16 locations · Updated 2026-11-05

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT07455851

    A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

    Regeneron Pharmaceuticals · 9 locations · Updated 2026-11-05

  • Heme · MyelomaRecruitingPhase 2NCT07825064

    Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

    Hoffmann-La Roche · 5 locations · Updated 2026-11-05

  • Heme · MyelomaRecruitingPhase 2NCT06971380

    Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

    Polina Stepensky · 1 locations · Updated 2026-11-04

  • Heme · MyelomaRecruitingPhase 2NCT04634552

    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

    Janssen Research & Development, LLC · 78 locations · Updated 2026-11-03

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06106945

    AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

    AstraZeneca · 46 locations · Updated 2026-10-30

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06953960

    A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

    AbbVie · 51 locations · Updated 2026-10-27

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT03761108

    Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

    Regeneron Pharmaceuticals · 40 locations · Updated 2026-10-26

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT04822337

    Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

    Wake Forest University Health Sciences · 2 locations · Updated 2026-10-26

  • Heme · MyelomaRecruitingPhase 2NCT06762769

    Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

    University College, London · 14 locations · Updated 2026-10-20

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06892522

    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

    AbbVie · 36 locations · Updated 2026-10-19

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT05850234

    AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

    AstraZeneca · 36 locations · Updated 2026-10-08

  • Heme · MyelomaRecruitingPhase 2NCT06297226

    Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 52 locations · Updated 2026-10-06

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT07336472

    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

    Fortvita Biologics (USA)Inc. · 6 locations · Updated 2026-09-25

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT07116616

    A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

    ModernaTX, Inc. · 10 locations · Updated 2026-09-23

  • Heme · MyelomaRecruitingPhase 2NCT05789303

    Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

    University of Chicago · 2 locations · Updated 2026-09-23

  • Heme · MyelomaRecruitingPhase 2NCT04661137

    A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

    Hackensack Meridian Health · 2 locations · Updated 2026-09-21

  • Heme · MyelomaNot yet recruitingPhase 2NCT07828522

    F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-09-18

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT07760454

    A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma

    UCARsgen Biotech Limited · 2 locations · Updated 2026-09-17

  • Heme · MyelomaRecruitingPhase 2NCT07585760

    CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-09-17

  • Heme · MyelomaRecruitingPhase 2NCT06832865

    ELISA in Relapsed/Refractory MM

    Massachusetts General Hospital · 3 locations · Updated 2026-09-16

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT07181941

    Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

    Fred Hutchinson Cancer Center · 1 locations · Updated 2026-09-16

  • Heme · MyelomaRecruitingPhase 2NCT06827860

    Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

    Larysa Sanchez · 1 locations · Updated 2026-09-14

  • Heme · MyelomaRecruitingPhase 2NCT05208307

    Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

    Emory University · 1 locations · Updated 2026-09-03

  • Heme · MyelomaNot yet recruitingPhase 1 / Phase 2NCT07601100

    Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

    Dana-Farber Cancer Institute · 2 locations · Updated 2026-09-03

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06988488

    A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

    Celgene · 22 locations · Updated 2026-09-02

  • Heme · MyelomaNot yet recruitingPhase 2NCT07029776

    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

    University of Arkansas · 1 locations · Updated 2026-09-02

  • Heme · MyelomaRecruitingPhase 2NCT06138275

    Elranatamab in R/R Multiple Myeloma

    Massachusetts General Hospital · 3 locations · Updated 2026-08-31

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT07479979

    Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

    Natalie Callander · 1 locations · Updated 2026-08-31

  • Heme · MyelomaRecruitingPhase 2NCT07227311

    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

    GlaxoSmithKline · 59 locations · Updated 2026-08-25

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT05714839

    A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

    GlaxoSmithKline · 44 locations · Updated 2026-08-19

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT05632380

    ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06669247

    A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

    Regeneron Pharmaceuticals · 9 locations · Updated 2026-08-05

  • Heme · MyelomaRecruitingPhase 2NCT07638683

    A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

    Shanghai Zhongshan Hospital · 1 locations · Updated 2026-08-03

  • Heme · MyelomaRecruitingPhase 2NCT06461988

    Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

    Stanford University · 1 locations · Updated 2026-07-17

  • Heme · MyelomaRecruitingPhase 2NCT05469893

    Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

    Irene Ghobrial, MD · 3 locations · Updated 2026-07-16

  • Heme · MyelomaRecruitingPhase 2NCT05847569

    Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

    Mayo Clinic · 1 locations · Updated 2026-07-14

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT07454187

    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

    Hangzhou Sumgen Biotech Co., Ltd. · 4 locations · Updated 2026-07-10

  • Heme · MyelomaRecruitingPhase 2NCT06140524

    A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

    Regeneron Pharmaceuticals · 39 locations · Updated 2026-07-08

  • Heme · MyelomaNot yet recruitingPhase 1 / Phase 2NCT07687004

    Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-07-07

  • Heme · MyelomaNot yet recruitingPhase 2NCT07614360

    Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

    GlaxoSmithKline · Locations not reported · Updated 2026-06-24

  • Heme · MyelomaRecruitingPhase 2NCT05145400

    Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

    UNC Lineberger Comprehensive Cancer Center · 5 locations · Updated 2026-06-02

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT05853965

    Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma

    Universitätsklinikum Hamburg-Eppendorf · 5 locations · Updated 2026-05-18

  • Heme · MyelomaRecruitingPhase 2NCT07107529

    Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

    European Myeloma Network B.V. · 29 locations · Updated 2026-04-15

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 1 / Phase 2NCT07523555

    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

    Beijing Biotech · 1 locations · Updated 2026-04-13

  • Heme · MyelomaNot yet recruitingPhase 1 / Phase 2NCT07510100

    Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

    Nanjing IASO Biotechnology Co., Ltd. · 3 locations · Updated 2026-04-03

  • Heme · MyelomaRecruitingPhase 2NCT06066346

    A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

    Memorial Sloan Kettering Cancer Center · 7 locations · Updated 2026-03-04

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06235229

    A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

    Gracell Biotechnologies (Shanghai) Co., Ltd. · 10 locations · Updated 2026-02-25

  • Heme · MyelomaRecruitingPhase 2NCT05530421

    Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

    University of Miami · 3 locations · Updated 2026-02-23

  • Heme · MyelomaNot yet recruitingPhase 1 / Phase 2NCT07421856

    Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

    Hebei Senlang Biotechnology Inc., Ltd. · Locations not reported · Updated 2026-02-19

  • Heme · MyelomaNot yet recruitingPhase 2NCT07348393

    A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Assistance Publique - Hôpitaux de Paris · 1 locations · Updated 2026-01-16

  • Heme · MyelomaRecruitingPhase 2NCT07312188

    A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

    Shandong New Time Pharmaceutical Co., LTD · 1 locations · Updated 2025-12-31

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06645678

    Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

    YOUNGIL KOH · 7 locations · Updated 2025-12-03

  • Heme · MyelomaNot yet recruitingPhase 2NCT06830733

    Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia

    Fundacion Clinic per a la Recerca Biomédica · 7 locations · Updated 2025-04-25

  • Heme · MyelomaRecruitingPhase 2NCT06140966

    Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2025-04-16

  • Heme · MyelomaRecruitingPhase 2NCT06668792

    An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

    Biocad · 20 locations · Updated 2025-02-04

  • Heme · MyelomaRecruitingPhase 2NCT05636787

    Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients

    Insel Gruppe AG, University Hospital Bern · 1 locations · Updated 2024-07-08

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06232096

    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

    Beijing Mabworks Biotech Co., Ltd. · 1 locations · Updated 2024-03-15

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT06246162

    Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma

    Affiliated Hospital of Nantong University · 1 locations · Updated 2024-02-07

  • Heme · MyelomaRecruitingPhase 1 / Phase 2NCT05521802

    A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

    Shanghai AbelZeta Ltd. · 1 locations · Updated 2023-03-24

  • Heme · MyelomaRecruitingPhase 2NCT05594797

    Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM

    Hrain Biotechnology Co., Ltd. · 2 locations · Updated 2022-12-09

  • Heme · MyelomaNot yet recruitingPhase 2NCT05054478

    Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation

    Assistance Publique - Hôpitaux de Paris · Locations not reported · Updated 2021-09-23

  • Heme · MyelomaRecruitingPhase 1NCT05651932

    A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

    K36 Therapeutics, Inc. · 29 locations · Updated 2026-11-18

  • Heme · MyelomaNot yet recruitingPhase 1NCT07927842

    BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma

    Liping Dou · 1 locations · Updated 2026-11-10

  • Heme · MyelomaRecruitingEarly Phase 1NCT07322159

    IASO206 in Patients With Relapsed/Refractory Multiple Myeloma

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-11-09

  • Heme · MyelomaRecruitingPhase 1NCT05137054

    A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Regeneron Pharmaceuticals · 42 locations · Updated 2026-11-05

  • Heme · MyelomaRecruitingPhase 1NCT06518551

    ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Omar Nadeem, MD · 3 locations · Updated 2026-11-02

  • Heme · MyelomaRecruitingPhase 1NCT06465316

    Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

    National Cancer Institute (NCI) · 17 locations · Updated 2026-10-27

  • Heme · MyelomaNot yet recruitingPhase 1NCT07874334

    Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis

    Hadassah Medical Organization · 1 locations · Updated 2026-10-20

  • Heme · MyelomaRecruitingPhase 1NCT06582017

    Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Nammi Therapeutics Inc · 11 locations · Updated 2026-10-20

  • Heme · MyelomaRecruitingPhase 1NCT07333430

    Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

    Hadassah Medical Organization · 1 locations · Updated 2026-10-16

  • Heme · MyelomaRecruitingPhase 1NCT07200089

    Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

    Washington University School of Medicine · 1 locations · Updated 2026-10-15

  • Heme · MyelomaRecruitingPhase 1NCT07073547

    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

    AstraZeneca · 13 locations · Updated 2026-09-25

  • Heme · MyelomaRecruitingNot reportedObservationalNCT06477783

    Study on the Clinical Efficacy of Teclistamab and Talquetamab

    Universitaire Ziekenhuizen KU Leuven · 17 locations · Updated 2026-09-25

  • Heme · MyelomaRecruitingPhase 1NCT07620275

    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

    Chinese PLA General Hospital · 3 locations · Updated 2026-09-15

  • Heme · MyelomaNot yet recruitingNot reportedObservationalNCT07746232

    Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"

    Fondazione EMN Italy Onlus · 10 locations · Updated 2026-09-09

  • Heme · MyelomaNot yet recruitingEarly Phase 1NCT07727668

    Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

    Shambavi Richard · 1 locations · Updated 2026-07-27

  • Heme · MyelomaNot yet recruitingPhase 1NCT07726160

    A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-07-24

  • Heme · MyelomaNot yet recruitingPhase 1NCT07720843

    TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

    Montefiore Medical Center · Locations not reported · Updated 2026-07-22

  • Heme · Myeloma, LymphomaRecruitingEarly Phase 1NCT07101705

    An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2026-07-21

  • Heme · MyelomaRecruitingPhase 1NCT07715630

    In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

    Chongqing Precision Biotech Co., Ltd · 1 locations · Updated 2026-07-20

  • Heme · MyelomaRecruitingPhase 1NCT06185751

    Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

    Washington University School of Medicine · 1 locations · Updated 2026-07-09

  • Heme · MyelomaRecruitingNot reportedObservationalNCT07663253

    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

    Shanghai Zhongshan Hospital · 13 locations · Updated 2026-06-23

  • Heme · MyelomaRecruitingPhase 1NCT07652138

    Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-06-16

  • Heme · MyelomaNot yet recruitingNot applicableNCT07646873

    PET-Enabled Dual-Energy CT in Multiple Myeloma

    University of California, Davis · 1 locations · Updated 2026-06-15

  • Heme · MyelomaNot yet recruitingPhase 1NCT07622862

    Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)

    Zhongshan Hospital (Xiamen), Fudan University · Locations not reported · Updated 2026-06-03

  • Heme · MyelomaRecruitingPhase 1NCT07541391

    Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

    Peter MacCallum Cancer Centre, Australia · 1 locations · Updated 2026-05-27

  • Heme · MyelomaRecruitingPhase 1NCT06896916

    Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

    AbbVie · 27 locations · Updated 2026-05-12

  • Heme · MyelomaRecruitingPhase 1NCT07377435

    DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

    David Avigan · 1 locations · Updated 2026-05-08

  • Heme · MyelomaRecruitingPhase 1NCT06799026

    A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

    David Avigan · 2 locations · Updated 2026-05-07

  • Heme · MyelomaRecruitingNot reportedObservationalNCT04888039

    Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"

    University Hospital, Toulouse · 1 locations · Updated 2026-04-29

  • Heme · MyelomaNot yet recruitingPhase 1NCT07537049

    BR101 in Patients With Relapsed/Refractory Multiple Myeloma

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 locations · Updated 2026-04-17

  • Heme · MyelomaRecruitingPhase 1NCT07529782

    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 5 locations · Updated 2026-04-14

  • Heme · MyelomaRecruitingNot reportedObservationalNCT06252792

    Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma

    FengYan Jin · 1 locations · Updated 2026-04-03

  • Heme · MyelomaRecruitingPhase 1NCT06630806

    A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

    Sanofi · 19 locations · Updated 2026-03-25

  • Heme · MyelomaRecruitingPhase 1NCT06348108

    Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Alfred Chung, MD · 1 locations · Updated 2026-03-13

  • Heme · MyelomaRecruitingEarly Phase 1NCT06142396

    Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

    Augusta University · 1 locations · Updated 2026-03-12

  • Heme · MyelomaRecruitingPhase 1NCT06623630

    Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

    Washington University School of Medicine · 1 locations · Updated 2026-03-11

  • Heme · MyelomaNot yet recruitingEarly Phase 1NCT07234721

    SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-02-10

  • Heme · MyelomaRecruitingPhase 1NCT06574568

    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

    Excyte Biopharma Ltd · 12 locations · Updated 2026-02-05

  • Heme · MyelomaRecruitingNot applicableNCT07359014

    Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

    Second Affiliated Hospital, Zhejiang University, School of Medicine · 1 locations · Updated 2026-01-22

  • Heme · MyelomaNot yet recruitingEarly Phase 1NCT07185490

    IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-01-20

  • Heme · MyelomaRecruitingEarly Phase 1NCT07336823

    JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

    Shenzhen Genocury Biotech Co., Ltd. · 1 locations · Updated 2026-01-13

  • Heme · MyelomaNot yet recruitingNot reportedObservationalNCT07320326

    ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

    Peking University People's Hospital · 1 locations · Updated 2026-01-06

  • Heme · MyelomaRecruitingNot applicableNCT07100067

    LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

    Nanjing Legend Biotech Co. · 4 locations · Updated 2025-12-29

  • Heme · MyelomaRecruitingNot reportedObservationalNCT07296627

    Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

    Peking University People's Hospital · 1 locations · Updated 2025-12-22

  • Heme · MyelomaRecruitingPhase 1NCT07179679

    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 14 locations · Updated 2025-12-11

  • Heme · MyelomaRecruitingEarly Phase 1NCT07249073

    CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-11-25

  • Heme · MyelomaRecruitingEarly Phase 1NCT06730256

    A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2025-10-01

  • Heme · MyelomaNot yet recruitingPhase 1NCT07114432

    RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

    Tianjin Medical University Cancer Institute and Hospital · 2 locations · Updated 2025-08-11

  • Heme · MyelomaRecruitingEarly Phase 1NCT06988059

    A Study of CT0596 in Plasma Cell Leukemia

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-08-01

  • Heme · MyelomaNot yet recruitingNot applicableNCT07018271

    A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients

    The First Affiliated Hospital of Soochow University · Locations not reported · Updated 2025-06-12

  • Heme · MyelomaRecruitingPhase 1NCT05219721

    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

    Chunrui Li · 1 locations · Updated 2025-06-11

  • Heme · MyelomaNot yet recruitingNot applicableNCT07015021

    The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

    The First Affiliated Hospital of Soochow University · Locations not reported · Updated 2025-06-11

  • Heme · MyelomaRecruitingEarly Phase 1NCT06999031

    A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

    The First Affiliated Hospital of Nanchang University · 1 locations · Updated 2025-05-31

  • Heme · MyelomaRecruitingPhase 1NCT05759793

    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

    Nanjing IASO Biotechnology Co., Ltd. · 1 locations · Updated 2025-05-20

  • Heme · MyelomaRecruitingEarly Phase 1NCT05846880

    VitD3 Supplementation in Patients With Multiple Myeloma

    Amany Keruakous, MD, MS. · 1 locations · Updated 2025-04-08

  • Heme · MyelomaNot yet recruitingNot applicableNCT06888752

    LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma

    First Affiliated Hospital of Wenzhou Medical University · Locations not reported · Updated 2025-03-21

  • Heme · MyelomaRecruitingNot reportedObservationalNCT06874530

    Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+

    IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 locations · Updated 2025-03-13

  • Heme · MyelomaRecruitingEarly Phase 1NCT06732232

    A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

    Shanghai Cell Therapy Group Co.,Ltd · 1 locations · Updated 2024-12-13

  • Heme · MyelomaRecruitingEarly Phase 1NCT06718270

    a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

    Shanghai Changzheng Hospital · 1 locations · Updated 2024-12-12

  • Heme · MyelomaRecruitingPhase 1NCT06700395

    A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 2 locations · Updated 2024-12-06

  • Heme · MyelomaRecruitingNot reportedObservationalNCT06682156

    Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2024-11-12

  • Heme · MyelomaRecruitingPhase 1NCT06644118

    A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

    Zhejiang University · 3 locations · Updated 2024-11-08

  • Heme · MyelomaNot yet recruitingPhase 1NCT06655519

    An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

    Peking University People's Hospital · Locations not reported · Updated 2024-10-23

  • Heme · MyelomaRecruitingPhase 1NCT06271252

    A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

    OriCell Therapeutics Co., Ltd. · 1 locations · Updated 2024-08-02

  • Heme · MyelomaNot yet recruitingNot applicableNCT06472479

    LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

    The First Affiliated Hospital with Nanjing Medical University · 4 locations · Updated 2024-06-28

  • Heme · MyelomaRecruitingNot reportedObservationalNCT06149910

    Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

    All4Cure · 1 locations · Updated 2024-05-03

  • Heme · MyelomaRecruitingEarly Phase 1NCT06045091

    To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

    Hrain Biotechnology Co., Ltd. · 1 locations · Updated 2023-09-21

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.